Circulating gamma-glutamyltransferase fractions in cirrhosis.

Background: Four GGT fractions (b-, m-, s-, and f-GGT) have been identified in human plasma and their concentrations and ratios vary in different pathological conditions. Aim: To assess the behavior of fractional GGT in cirrhotic patients evaluated for liver transplantation. Methods: This was a single-center, cross-sectional study; GGT fractions were determined by gel-filtration chromatography. Results: 264 cirrhotic patients (215 males; median age 54.5 years) were included and compared against a group of 200 healthy individuals (100 males; median age 41.5). Median (25th-75th percentile) total and fractional GGT were higher in cirrhotics, with s-GGT showing the greatest increase [36.6 U/L (21.0-81.4) vs. 5.6 U/L (3.2-10.2), (p<0.0001)], while the median b-GGT/s-GGT ratio was lower in cirrhotics than in healthy controls [0.06 (0.04-0.10)] vs. 0.28 (0.20-0.40), p<0.0001]. The ratio showed higher diagnostic accuracy (ROC-AUC, 95% CI: 0.951, 0.927-0.969) then either s-GGT (0.924, 0.897-0.947; p<0.05) or total GGT (0.900, 0.869-0.925; p<0.001). The diagnostic accuracy of the ratio was maintained (0.940, 0.907-0.963) in cirrhotic patients (n=113) with total GGT values within the reference range. The s-GGT fraction consisted of two components, with one (s2-GGT) showing a significant positive correlation with serum AST, ALT, LDH, ALP and bilirubin, and negative with albumin. The b-GGT fraction showed a positive correlation with albumin, fibrinogen, and platelet counts, and negative with INR, bilirubin and LDH. Conclusions: The ratio performs as a sensitive biomarker of the liver parenchymal rearrangement, irrespective of etiology of cirrhosis and presence of hepatocellular carcinoma, even in patients with total GGT values within the reference range

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

We reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male-73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n\u2009=\u2009221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n\u2009=\u200954, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustained virological response at week 12 post-treatment (SVR12). Liver function changes between baseline and follow up were assessed in 228 patients. 240 patients achieved SVR12 (87.3%), post transplant and HIV co-infected patients were equally distributed among SVR and no SVR (35% vs 34.3%; p\u2009=\u20090.56 and 24.2% vs 11.4%, p\u2009=\u20090.13, respectively). SVR rate was significantly higher with the combination DCV\u2009+\u2009SOF compared with DCV\u2009+\u2009SIM or ASU (93.2% vs 63.0%, p\u2009<\u20090.0001). Bilirubin value (OR: 0.69, CI95%: 0.54-0.87, p\u2009=\u20090.002) and regimen containing SOF (OR: 9.99, CI95%: 4.09-24.40; p\u2009<\u20090.001) were independently related with SVR. Mean albumin and bilirubin values significantly improved between baseline and follow-up week 12. DCV-based antiviral therapy was well tolerated and resulted in a high SVR when combined with SOF either in pre-transplant and in OLT patients and in "difficult to treat" HCV genotypes. Regimens containing DCV in combination with NS3 protease inhibitors obtained suboptimal results

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows

With the introduction of direct-acting antiviral agents (DAA), the rate of sustained virological response (SVR) in the treatment of hepatitis C virus (HCV) has radically improved to over 95%. Robust scientific evidence supports a beneficial role of SVR after interferon therapy in the progression of cirrhosis, resulting in a decreased incidence of hepatocellular carcinoma (HCC). However, a debate on the impact of DAAs on the development of HCC is ongoing. This review aimed to analyse the scientific literature regarding the risk of HCC in terms of its recurrence and occurrence after the use of DAAs to eradicate HCV infection. Among 11 studies examining HCC occurrence, the de novo incidence rate ranged from 0 to 7.4% (maximum follow-up: 18 mo). Among 18 studies regarding HCC recurrence, the rate ranged from 0 to 54.4% (maximum "not well-defined" followup: 32 mo). This review highlights the major difficulties in interpreting data and reconciling the results of the included studies. These difficulties include heterogeneous cohorts, potential misclassifications of HCC prior to DAA therapy, the absence of an adequate control group, short follow-up times and different kinds of follow-up. Moreover, no clinical feature-based scoring system accounts for the molecular characteristics and pathobiology of the tumours. Nonetheless, this review does not suggest that there is a higher rate of de novo HCC occurrence or recurrence after DAA therapy in patients with previous HCV infection. \ua9 2018 The Author(s). Published by Baishideng Publishing Group Inc. All rights reserved

Epistolari dal Due al Seicento. Modelli, questioni ecdotiche, edizioni, cantieri aperti (Gargnano del Garda, 29 settembre - 1° ottobre 2014)

Nei secoli passati, la lettera era l'unico mezzo di comunicazione: familiare, amichevole, d'ufficio o di servizio, ma anche strumento di dibattito politico e culturale. Lo studio degli epistolari dei singoli ma anche delle reti di comunicazione e di scambio è uno dei grandi temi della ricerca europea contemporanea. Vi si inserisce questo secondo volume dei "Quaderni di Gargnano", che - volgendosi sia alla produzione latina sia a quella volgare dal Due al Seicento - si sofferma su problemi metodologici e casi significativi, con impostazioni e tagli diversi: dall'ecdotica alla filologia, dall'archivistica, alla storia, alla storia delle discipline

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

Background: Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development of stage 653 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of stage 653 CKD in a large cohort of patients affected by T1DM. Methods: A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the Italian Association of Clinical Diabetologists (Associazione Medici Diabetologi, AMD) initiative constitutes the study population. Urinary albumin excretion (ACR) and estimated GFR (eGFR) were retrieved and analyzed. The incidence of stage 653 CKD (eGFR &lt; 60 mL/min/1.73 m2) or eGFR reduction &gt; 30% from baseline was evaluated. Results: The mean estimated GFR was 98 \ub1 17 mL/min/1.73m2 and the proportion of patients with albuminuria was 15.3% (n = 654) at baseline. About 8% (n = 337) of patients developed one of the two renal endpoints during the 4-year follow-up period. Age, albuminuria (micro or macro) and baseline eGFR &lt; 90 ml/min/m2 were independent risk factors for stage 653 CKD and renal function worsening. When compared to patients with eGFR &gt; 90 ml/min/1.73m2 and normoalbuminuria, those with albuminuria at baseline had a 1.69 greater risk of reaching stage 3 CKD, while patients with mild eGFR reduction (i.e. eGFR between 90 and 60 mL/min/1.73 m2) show a 3.81 greater risk that rose to 8.24 for those patients with albuminuria and mild eGFR reduction at baseline. Conclusions: Albuminuria and eGFR reduction represent independent risk factors for incident stage 653 CKD in T1DM patients. The simultaneous occurrence of reduced eGFR and albuminuria have a synergistic effect on renal function worsening

La filologia e la stilistica di Dante Isella. Per un\u2019antologia, a cura di Stefano Carrai e Paola Italia, \u201cEcdotica\u201d, n. 15 (2018), pp. 185-238 (Introduzione pp. 185-88).

Il saggio introduce e propone a una platea di studiosi internazionali, quale \ue8 quella di "Ecdotica", una antologia di testi critici del filologo e critico Dante Isella (1922-2007), docente presso l'Universit\ue0 di Pavia e il Politecnico Federale di Zurigo, autore di numerose edizioni critiche e studi stilistici di autori della letteratura italiana, da Parini a Gadda, e fondatore della Filologia d'autore. Segue una serie di brani selezionati dalle principali edizioni critiche, da Parini a Gadda, da Sereni a Manzoni, e studi, da Spitzer a Dossi, da Porta a Tessa a Montale, del filologo lombardo

Failure to respond to sofosbuvir and ribavirin after liver transplantation

Background: Predictors of failure of combined therapy with sofosbuvir (SOF) and ribavirin (RIBA) in liver transplant (LT) recipients affected with recurrent hepatitis C virus (HCV) are largely unknown. Materials and methods: This was a retrospective analysis of adult, maintenance LT recipients enrolled in the SOF compassionate program at a single center. Patients were included into current analysis if: adult (³18 years), F3-F4 at baseline, and receiving at least one dose of SOF+RIBA. Primary endpoint was treatment effcacy as end of treatment (EOT), and sustained viral responses at 4 (SVR4) and 12 weeks (SVR12). The secondary endpoint was identifcation of predictors of SVR12 among all clinical variables retrieved with medical record review. Results: Among 176 LT recipients enrolled in the compassionate program, 163 (male 83.5%; median age [range] 58 [30-75] years) were treated with a 24-week course of SOF+RIBA and included into current analysis. Treatment was initiated at a median of 38 months [30-75] after transplantation. At baseline, mean (SD) fbrosis was 15.7 (7.8) KPa; mean (SD) HCV RNA was 1,145,288.7 (2,073,664.1) IU/mL, and genotype (GT) 1-4 was present in 123 (75.5%) cases. Child-Pugh (C-P) status was B/C in 30 (18.4%) and A in 133 (81.6%), and mean (SD) MELD score was 16.2 (3.6). Six (3.0%) patients were affected with post-transplant fbrosing cholestatic hepatitis. One-hundred-sixty-two (99.4%) patients completed the 24-week treatment course, and EOT, SVR4 and SVR12 were 100% (163/163), 85.2% (138/162), and 83.3% (135/162), respectively. The only variable associated with SVR12 was baseline serum albumin (r = 0.41; p=0.0001), while total bilirubin (r=-0.04; p=0.78), INR (r =-0.13; p=0.25), serum creatinine (r=0.17; p=0.12), C-P status (chi-square=1.41; p =0.23), MELD (r=-0.12; p=0.24), and severity of fbrosis (r=-0.19; p=0.11) were not signifcantly associated. Conclusions: Our experience suggests that failure to respond to a combined regimen with SOF+RIBA is associated with lower serum albumin levels in LT recipients with recurrent HCV graft disease